CSL Behring: EU Could Support Gene Therapy Access By Sharing Contracting ‘Best Practices’

While CSL Behring has successfully negotiated reimbursement contracts for its one-time gene therapy Hemgenix in several European countries, it says there are still “barriers to innovative contracting solutions” in some member states that need to be addressed.